Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture
Journal of Controlled Release · 2023-02 · 354 · 354-367
DOI: 10.1016/j.jconrel.2023.01.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-02. Verfasst von Yi-Chen Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529…. Hauptthemen laut MEDLINE: Liposomes, Antigen-Antibody Complex. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST, Academia Sinica, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Methoxy polyethylene glycol (mPEG) is attached to many proteins, peptides, nucleic acids and nanomedicines to improve their biocompatibility. Antibodies that bind PEG are present in many individuals and can be generated upon administration of pegylated therapeutics. Anti-PEG antibodies that bind to the PEG "backbone" can accelerate drug clearance and detrimentally affect drug activity and safety, but no studies have examined how anti-methoxy PEG (mPEG) antibodies, which selectively bind the terminus of mPEG, affect pegylated drugs. Here, we investigated how defined IgG and IgM monoclonal antibodies specific to the PEG backbone (anti-PEG) or terminal methoxy group (anti-mPEG) affect pegylated liposomes or proteins with a single PEG chain, a single branched PEG chain, or multiple PEG chains. Large immune complexes can be formed between all pegylated compounds and anti-PEG antibodies but only pegylated liposomes formed large immune complexes with anti-mPEG antibodies. Both anti-PEG IgG and IgM antibodies accelerated the clearance of all pegylated compounds but anti-mPEG antibodies did not accelerate clearance of proteins with a single or branched PEG molecule. Pegylated liposomes were primarily taken up by Kupffer cells in the liver, but both anti-PEG and anti-mPEG antibodies directed uptake of a heavily pegylated protein to liver sinusoidal endothelial cells. Our results demonstrate that in contrast to anti-PEG antibodies, immune complex formation and drug clearance induced by anti-mPEG antibodies depends on pegylation architecture; compounds with a single or branched PEG molecule are unaffected by anti-mPEG antibodies but are increasingly affected as the number of PEG chain in a structure increases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
- Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
- Department of Medical Laboratory Sciences, Pharmacological and Diagnostic Research Centre, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.
- Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan; Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiu…
Förderung
- MOST
- Academia Sinica
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Lin, Y. C., Chen, B. M., Tran, T. T. M., Chang, T. C., Al-Qaisi, T. S., & Roffler, S. R. (2023). Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. Journal of Controlled Release, 354, 354-367. https://doi.org/10.1016/j.jconrel.2023.01.021
Vancouver
Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR. Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture. Journal of Controlled Release. 2023;354:354-367. doi:10.1016/j.jconrel.2023.01.021
BibTeX
@article{Lin2023,
author = {Lin, Yi-Chen and Chen, Bing-Mae and Tran, Trieu Thi My and Chang, Tien-Ching and Al-Qaisi, Talal Salem and Roffler, Steve R},
title = {Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture},
journal = {Journal of Controlled Release},
year = {2023},
volume = {354},
pages = {354--367},
doi = {10.1016/j.jconrel.2023.01.021}
}
EUVIMED